Human papillomavirus: Current prevalence and future protection

Sexually Transmitted Diseases

Volumn 33, Issue 8, 2006, Pages 509-511

  Bauer, Heidi M ^a   Ault, Kevin ^b  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT HEALTH; AGE DISTRIBUTION; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CONDYLOMA; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIPHTHERIA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; EDITORIAL; FEMALE GENITAL TRACT INFECTION; GENITAL TRACT INFECTION; HEALTH SURVEY; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION PREVENTION; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MOUTH INFECTION; PAPILLOMATOSIS; PERTUSSIS; POPULATION RESEARCH; PRECANCER; RECURRENT RESPIRATORY PAPILLOMATOSIS; RISK REDUCTION; SCREENING TEST; SEROPREVALENCE; SEX DIFFERENCE; SEXUALLY TRANSMITTED DISEASE; STATISTICAL DISTRIBUTION; TETANUS; UNITED STATES; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VAGINA SMEAR; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; VIRUS INFECTION; WART VIRUS;

FEMALE; FORECASTING; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UNITED STATES; VACCINATION; VIRAL VACCINES;

EID: 33746413743     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000225323.51240.bc     Document Type: Editorial

References (32)

1. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 2006; 33:502-508.
2. Palmisano ME, Gaffga AM, Daigle J, et al. Detection of human papillomavirus DNA in self-administered vaginal swabs as compared to cervical swabs. Int J STD AIDS 2003; 14:560-567.
3. Baseman IG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32(suppl 1):S16-24.
4. Centers for Disease Control and Prevention. Human Papillomavirus (HPV) Infection. Available at: http://www.cdc.gov/std/hpv/. Accessed March 27, 2006.
5. American Cancer Society. Overview: Cervical Cancer. Available at: http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?dt=8. Accessed March 27, 2006.
6. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
7. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364:1757-1765.
8. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
9. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
10. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367(9518):1247-1255.
11. Harper DM, for the FUTURE I Investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). Paper presented at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 11-13, 2005, Washington DC.
12. Steinbrook R. The potential of human papillomavirus vaccines. N Engl J Med 2006; 354:1109-1112.
13. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nature Reviews 2004; 2:343-347.
14. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-615.
15. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-789.
16. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48.
17. Advisory Committee on Immunization Practices. February 2006 ACIP Meeting Presentation Slides. Available at: http://www.cdc.gov/nip/ACIP/mtg-slides-feb06. htm. Accessed April 1, 2006.
18. Centers for Disease Control and Prevention. Youth risk behavioral surveillance - 2003. MMWR Morb Mortal Wkly Rep 2004; 53:SS-2.
19. Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 2005; 37(suppl):S10-16.
20. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol 2005; 17:476-482.
21. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics 2005; 116:496-505.
22. American Academy of Pediatrics, Committee on Infectious Diseases. Prevention of pertussis among adolescents: Recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 2006; 117:965-978.
23. Zimet GD. Improving adolescent health: Focus on HPV vaccine acceptance. J Adolesc Health 2005; 37(suppl):S17-23.
24. Zimet GD. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol 2006; 18(suppl 1):s23-28.
25. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003; 14:300-306.
26. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000; 9:47-50.
27. Zimet GD, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005; 37:179-186.
28. Anhang R, Goodman A, Goldie SJ. HPV communication: Review of existing research and recommendations for patient education. CA Cancer J Clin 2004; 54:248-259.
29. Davis K, Dickman LD, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004; 8:188-194.
30. Franco LL, Harper DM. Vaccination against human papillomavirus infection: A new paradigm in cervical cancer control. Vaccine 2005; 23:2388-2394.
31. MacKenzie D. Will Cancer Vaccine Get to All Women? Available at: http://www.newscientist.com/channel/sex/mg18624954.500. Accessed March 27, 2006.
32. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Koutsky L. The effect of consistent condom use on the risk of genital HPV infection among newly sexually active women. Paper presented at the 16th Biennial Meeting of the International Society for Sexually Transmitted Disease Research (ISSTDR), July 10-13, 2005, Amsterdam, The Netherlands.